Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| UPLIZNA | 60.8 | | | | | | | |
| Orphan and Rheumatology | | | | | 680.9 | | | |
| Inflammation | 330.9 | 412.8 | 449.0 | 439.2 | 375.3 | | | |
| KRYSTEXXA | 565.5 | 405.8 | 342.4 | 258.9 | 156.5 | | | |
| Other | 2,269.3 | 1,381.8 | 508.6 | 509.4 | | | | |
| Total revenues [+] | 3,226.4 | 2,200.4 | 1,300.0 | 1,207.6 | 1,056.2 | 981.1 | 757.0 | 297.0 |
| Products | 3,226.4 | 2,200.4 | 1,300.0 | 1,207.6 | 1,056.2 | | 2,057.3 | 600.8 |
| Revenue growth [+] | 46.6% | 69.3% | 7.7% | 14.3% | 7.7% | 29.6% | 154.9% | 301.2% |
| Inflammation | -19.8% | -8.1% | 2.2% | 17.0% | | | | |
| KRYSTEXXA | 39.3% | 18.5% | 32.2% | 65.5% | | | | |
| RAVICTI | 11.6% | 14.4% | 0.9% | 16.9% | | | | |
| Cost of goods sold | 794.5 | 532.7 | 362.2 | 391.3 | 493.4 | 392.0 | 219.5 | 78.8 |
| Gross profit | 2,431.9 | 1,667.7 | 937.9 | 816.3 | 562.9 | 589.1 | 537.5 | 218.2 |
| Gross margin | 75.4% | 75.8% | 72.1% | 67.6% | 53.3% | 60.0% | 71.0% | 73.5% |
| Selling, general and administrative [+] | 1,446.4 | 973.2 | 697.1 | 692.5 | 655.1 | 603.0 | 440.3 | 209.2 |
| Sales and marketing | | | | | | | | 120.3 |
| General and administrative | | | | | | | | 89.0 |
| Research and development | 432.0 | 209.4 | 103.2 | 82.8 | 225.0 | 60.7 | 41.9 | 17.5 |
| Other operating expenses | -26.3 | -1.6 | -0.2 | -15.4 | -6.1 | | | |
| EBITDA [+] | 933.6 | 766.2 | 375.0 | 306.1 | -55.0 | 147.0 | 193.7 | 25.5 |
| EBITDA growth | 21.8% | 104.3% | 22.5% | -656.7% | -137.4% | -24.1% | 659.1% | -176.1% |
| EBITDA margin | 28.9% | 34.8% | 28.8% | 25.4% | -5.2% | 15.0% | 25.6% | 8.6% |
| Depreciation | 17.5 | 24.3 | 6.7 | 6.1 | 6.6 | 5.0 | 5.4 | 1.7 |
| EBITA | 916.1 | 741.9 | 368.2 | 300.0 | -61.6 | 142.1 | 188.3 | 23.8 |
| EBITA margin | 28.4% | 33.7% | 28.3% | 24.8% | -5.8% | 14.5% | 24.9% | 8.0% |
| Amortization of intangibles | 336.3 | 255.1 | 230.4 | 243.6 | 249.5 | 216.7 | 132.9 | 32.3 |
| EBIT [+] | 579.8 | 486.7 | 137.8 | 56.4 | -311.1 | -74.6 | 55.4 | -8.5 |
| EBIT growth | 19.1% | 253.2% | 144.5% | -118.1% | 316.8% | -234.8% | -752.1% | -80.2% |
| EBIT margin | 18.0% | 22.1% | 10.6% | 4.7% | -29.5% | -7.6% | 7.3% | -2.9% |
| Non-recurring items [+] | 36.7 | -3.3 | 11.2 | 18.5 | 28.4 | 71.3 | | |
| Asset impairment | 12.4 | 1.7 | | 46.1 | 22.3 | 71.3 | | |
| Loss (gain) on sale of assets | -2.0 | -4.9 | 11.0 | -43.0 | 1.2 | | | |
| Interest expense | 81.1 | 59.6 | 87.1 | 121.7 | 126.5 | 86.6 | 69.9 | 23.8 |
| Interest expense | 81.1 | 59.6 | 87.1 | 121.7 | 126.5 | 86.6 | 69.9 | 23.8 |
| Other income (expense), net [+] | 0.8 | -28.8 | -59.7 | 0.6 | 7.2 | 5.7 | -118.2 | -237.4 |
| Gain (loss) on sale of assets | | | | | 8.0 | | | |
| Gain (loss) on investments | | | | | | | -29.0 | |
| Gain (loss) on debt retirement | | -31.9 | -58.8 | | -1.0 | | | |
| Gain (loss) on foreign currency transactions | -1.0 | -0.3 | 0.0 | -0.2 | -0.3 | -1.0 | -1.2 | -3.9 |
| Gain (loss) on acquisitions / transactions | | | | | | | | 22.2 |
| Other | 1.8 | 3.4 | -0.9 | 0.8 | 0.4 | 6.7 | -10.3 | -11.3 |
| Pre-tax income | 462.8 | 401.6 | -20.2 | -83.1 | -458.8 | -226.8 | -132.7 | -269.7 |
| Income taxes | -71.7 | 11.8 | -593.2 | -44.8 | -108.7 | -61.3 | -172.2 | -6.1 |
| Tax rate | | 3.0% | 2933.4% | 53.8% | 23.7% | 27.0% | 129.8% | 2.3% |
| Net income | 534.5 | 389.8 | 573.0 | -38.4 | -350.1 | -165.6 | 39.5 | -263.6 |
| Net margin | 16.6% | 17.7% | 44.1% | -3.2% | -33.1% | -16.9% | 5.2% | -88.8% |
| |
| Basic EPS [+] | $2.37 | $1.91 | $3.13 | ($0.23) | ($2.15) | ($1.03) | $0.27 | ($3.15) |
| Growth | 24.0% | -39.0% | -1456.1% | -89.2% | 108.3% | -487.8% | -108.4% | 34.5% |
| Diluted EPS [+] | $2.27 | $1.81 | $2.79 | ($0.23) | ($2.15) | ($1.03) | $0.25 | ($3.15) |
| Growth | 25.3% | -35.2% | -1308.8% | -89.2% | 108.3% | -506.4% | -108.1% | 34.5% |
| |
| Shares outstanding (basic) [+] | 225.6 | 204.0 | 182.9 | 166.2 | 163.1 | 160.7 | 148.8 | 83.8 |
| Growth | 10.6% | 11.5% | 10.1% | 1.9% | 1.5% | 8.0% | 77.7% | 31.6% |
| Shares outstanding (diluted) [+] | 235.7 | 215.3 | 205.2 | 166.2 | 163.1 | 160.7 | 155.9 | 83.8 |
| Growth | 9.5% | 4.9% | 23.5% | 1.9% | 1.5% | 3.1% | 86.2% | 31.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|